To date, only one randomized prospective study has investigated the protective effect of GnRH in women with ovarian cancer who received chemotherapy, i.e., multi-drug regimens of bleomycin/etoposide/cisplatin/taxol/carboplatin or taxol/cisplatin or the vincristine/actinomycin/cyclophos-phamide regimen. Here, GNRH1 is linked to ovarian carcinoma.